Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
高选择性、非共价（可逆） BTK 抑制剂吡托布替尼的临床前表征
期刊:Blood
影响因子:21
doi:10.1182/blood.2022018674
Eliana B Gomez, Kevin Ebata, Hetal S Randeria, Mary S Rosendahl, E Peder Cedervall, Tony H Morales, Lauren M Hanson, Nicholas E Brown, Xueqian Gong, Jennifer Stephens, Wenjuan Wu, Isabel Lippincott, Karin S Ku, Richard A Walgren, Paolo B Abada, Joshua A Ballard, Charles K Allerston, Barbara J Brandh
